Amongst them, the BCL-2 specific BH3-mimetic venetoclax5 shows considerable clinical promise and is approved for the treatment of chronic lymphocytic leukaemia (CLL)6 and in combination therapy to treat acute myeloid leukaemia (AML)7,8. The gene discussed is BCL2; the disease is acute myeloid leukemia.